Shanna Hogeling

Dr. Shanna Hogeling is a researcher at the University of Groningen specializing in acute myeloid leukemia (AML) research. She is affiliated with the Department of Hematology at the University Medical Center Groningen and works within the research group led by Professor Jan Jacob Schuringa.

Her research focuses on acute myeloid leukemia, with particular expertise in KMT2A-altered leukemias, menin-KMT2A inhibition therapy, cancer immunology, and clonal evolution. Dr. Hogeling investigates novel therapeutic targets and mechanisms of immune evasion in AML, with significant contributions to understanding how M2 macrophages drive leukemic transformation through resistance to phagocytosis and alterations in mitochondrial metabolism.

Her publication record shows a clear trajectory of impactful research in hematology/oncology, with recent first-author papers in high-impact journals including Haematologica (2025), Blood (2024), and Science Advances (2023). Her work demonstrates an integration of molecular biology, cancer immunology, and translational research approaches to develop more effective AML treatments.

Dr. Hogeling has established productive collaborations with both academic and industry partners, including significant work with Janssen Pharmaceuticals on the menin-KMT2A inhibitor JNJ-75276617 (bleximenib). Her research has been recognized through citations in Scopus and mentions in news outlets, patents, and Wikipedia pages, indicating growing influence in the hematology research community.

Her laboratory work focuses on developing targeted therapies for AML, investigating tumor microenvironment interactions, and creating new methodologies like CombiFlow for tracking clonal evolution in leukemia patients. This research has direct implications for improving diagnostic approaches and treatment outcomes for AML patients.